Urothelial cancer drugs market to reach $8.21 billion by 2030 at 19.4% CAGR, driven by rising prevalence of urothelial cancer and increasing demand for chemotherapy.
Read More
Urology supplements market to reach $2.89 billion by 2030 at 8.0% CAGR, driven by increasing prevalence of urinary tract infections.
Read More
Urokinase market to reach $2.38 billion by 2030 at 5.6% CAGR, driven by growing burden of cardiovascular diseases worldwide.
Read More
Urinary retention drug market to reach $5.39 billion by 2030 at 5.7% CAGR, driven by rising prevalence of urinary disorders among aging populations.
Read More
Urinary ph modifier market to reach $4.11 billion by 2030 at 5.4% CAGR, driven by increasing prevalence of renal failure and preventive healthcare awareness.
Read More
Urea cycle disorders treatment market to reach $1.71 billion by 2030 at 4.6% CAGR, driven by rising number of chronic kidney disorder cases.
Read More
Unit dose manufacturing market to reach $106.79 billion by 2030 at 22.3% CAGR, driven by rising healthcare spending and focus on medication safety.
Read More
Ublituximab market to reach $2.24 billion by 2030 at 12.3% CAGR, driven by rising incidence of autoimmune disorders and improved diagnostic awareness.
Read More
Tyrosine kinase inhibitors market to reach $95.44 billion by 2030 at 8.9% CAGR, driven by increasing prevalence of cancer and adoption of targeted therapies.
Read More
Tylosin market to reach $1 billion by 2030 at 4.9% CAGR, driven by rising meat production and modernization of livestock farming practices.
Read More